Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Chemotherapy  (8)
  • Sprague-Dawley-Ratten  (3)
  • Antitumor activity  (2)
  • Metastatic breast cancer  (2)
  • 1
    Electronic Resource
    Electronic Resource
    On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer (1987)
    Springer
    Journal of molecular medicine 65 (1987), S. 959-966 
    Details
    ISSN: 1432-1440
    Keywords: Metastatic breast cancer ; Hormone monotherapy ; Tamoxifen ; Medroxyprogesterone acetate ; Aminoglutethimide ; Remission rates and duration ; Survival times
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary We analyzed the results of clinical studies on the therapeutic efficacy of hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in metastatic breast cancer, which were published between 1971 and 1986 and involved altogether 7000 patients. The overall response rates in patients treated with these hormonal single agents at various dose levels ranged from 31%–42%. When only estrogen receptor-positive patients were considered, the response rates lay between 41% and 54% in groups which were treated with the antiestrogenic agents tamoxifen or aminoglutethimide. The duration of remission was 12 months for tamoxifen- and aminoglutethimide-treated women, whereas medroxy-progesterone acetate effected remissions lasting from 6–16 months. The overall mean survival from start of therapy in tamoxifen- and aminoglutethimide-treated groups was 20 months, whereas information concerning this therapeutic parameter was available only in a minority of medroxyprogesterone acetate-treated groups. With respect to the response by site of metastatic lesions, all three agents caused a significantly higher degree of remissions in the soft tissue as compared to visceral disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01717830
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds (1983)
    Springer
    Journal of cancer research and clinical oncology 105 (1983), S. 109-110 
    Details
    ISSN: 1432-1335
    Keywords: cis-Dihalogenobis(1-phenyl-1,3-butanedionato)-titanium(IV) ; Antitumor activity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against L 1210 leukemia as compared with cis-diamminedichloroplatinum(II) (Cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed an enhanced effect and a lower toxicity compared with Cisplatin.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00391842
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Efficacy of β-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats (1987)
    Springer
    Journal of cancer research and clinical oncology 113 (1987), S. 446-450 
    Details
    ISSN: 1432-1335
    Keywords: Bis-β-diketonato metal complexes of titanium, zirconium, and hafnium ; Budotitane ; Acetoxymethylmethylnitrosamine-induced autochthonous colorectal tumors ; Antitumor activity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Bis-β-diketonato complexes of titanium, zirconium, and hafnium were tested against autochthonous colorectal tumors in rats. The model was found to reflect the clinical situation most closely. of the compounds tested, budotitane was the most effective in terms of decrease in tumor weight and number and in increasing the lifespan of the treated animals. The therapeutic efficiency was superior to that of 5-fluorouracil, which so far has been the drug with the best activity in patients suffering from colon cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00390038
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Experimental investigation on the influence upon chemical carcinogenesis: 4th communication (1979)
    Springer
    Journal of cancer research and clinical oncology 93 (1979), S. 57-66 
    Details
    ISSN: 1432-1335
    Keywords: 1,2-Dimethylhydrazine carcinogenesis ; Colon ; Sprague-Dawley rats ; Different diets ; 1,2-Dimethylhydrazin-Carcinogenese ; Kolon ; Sprague-Dawley-Ratten ; Verschiedene Diäten
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es wurde in 446 Sprague-Dawley-Ratten untersucht, ob die Carcinogenese von 1,2-Dimethylhydrazin (DMH) (Applikationen von 30 mg/kg Körpergewicht für 7 Monate) durch verschiedene Diäten (vegetarische, fett- und cholesterinreiche sowie kohlehydratreiche) beeinflußt werden kann. Ratten, die mit einer vegetarischen oder einer kohlehydratreichen Diät ernährt wurden, zeigten eine deutlich längere Induktionszeit (mediane Induktionszeit 347 bzw.323 Tage) für maligne Tumoren (Colon, Niere, Leber, Gehörgang) als die Tiere der anderen Testgruppen (mediane Induktionszeit zwischen 250 und 282 Tagen); Tiere, die mit einer kohlehydratreichen Diät ernährt wurden, entwickelten mehr benigne Lebertumoren (86%) als Tiere, die mit einer Standarddiät (19%) oder einer vegetarischen Diät (14%) ernährt wurden. Es ist wahrscheinlich, daß quantitative Unterschiede in der Carcinogenbehandlung für einige der festgestellten Unterschiede verantwortlich sind.
    Notes: Summary In a total of 446 Sprague-Dawley rats it was tested whether colon carcinogenesis induced by 1,2-dimethylhydrazine (DMH) (7-monthly applications of 30 mg/kg bodyweight) can be influenced by different diets (vegetarian, high fat, and high cholesterol and rich in carbohydrates). The rats treated with a vegetarian diet or a diet that was rich in carbohydrates showed apparently longer induction times (median induction time 347 days and 323 days, respectively) of the malignant tumors (colon, kidney, liver, ear duct) than animals of the other test groups (median induction times between 250 and 282 days); animals treated with the diet that was rich in carbohydrates developed more benign liver tumors (86%) than animals treated with a standard (19%) or vegetarian diet (14%). It is emphasized that quantitative differences in carcinogen treatment might be responsible for some of the differences observed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00451440
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Chemotherapy of autochthonous leukemias induced by 7,12-dimethylbenz(a)anthracene in long evans rats (1980)
    Springer
    Journal of cancer research and clinical oncology 96 (1980), S. 157-162 
    Details
    ISSN: 1432-1335
    Keywords: Autochthonous (primary) rat leukemia ; 7,12 Dimethylbenz(a)anthracene ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A total of 111 autochthonous (primary) acute rat leukemias of the diffuse-hepatic type which had been induced by 7,12-dimethylbenz(a)anthracene were treated with mono- and combination chemotherapy. The survival time of treated rats increased significantly compared to untreated controls. A combination of vincristine (VCR), adriamycin (ADR), and cytosine arabinoside (Ara-C) was superior to a combination of VCR and ADR as well as to a monotherapy with Cyclophosphamide, BCNU, VCR, ADR, and Ara-C.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00405500
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Comparative chemotherapeutic investigations on transplanted and autochthonous acute rat leukemias (1981)
    Springer
    Journal of cancer research and clinical oncology 100 (1981), S. 239-246 
    Details
    ISSN: 1432-1335
    Keywords: Transplanted rat leukemia L 5222 ; Autochthonous rat leukemia ; Chemotherapy ; Transplantierte Rattenleukämie L 5222 ; Autochthone Rattenleukämie ; Chemotherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Der Effekt einer klinisch wirksamen Substanzkombination (Vincristin, Adriamycin, Cytosin-Arabinosid) gegenüber einer transplantierten akuten Rattenleukämie (L 5222) und gegenüber autochthonen akuten Rattenleukämien wird in einem nichttoxischen Dosisbereich verglichen. Die Ratten mit transplantierter Leukämie verstarben nach vier, ohne Unterbrechung gegebenen Therapiecyclen; Remissionen wurden nicht erreicht. Die gleiche Behandlung, die zusätzlich durch einwöchige therapiefreie Intervalle unterbrochen werden konnte, bewirkte bei allen Ratten mit autochthoner Leukämie eine komplette Remission. Das unterschiedliche Ansprechen beider Leukämieformen auf die Therapie wird in erster Linie auf Unterschiede in der Kinetik zurückgeführt. Die Vergleichbarkeit transplantierter und autochthoner Rattenleukämien mit der akuten Leukämie des Menschen wird diskutiert.
    Notes: Summary The effect of a clinically active drug combination (vincristine, adriamycin, cytosine arabinoside) against (1) a transplanted acute rat leukemia (L 5222) and (2) autochthonous acute rat leukemias is compared in a non-toxic dose range. After four therapy cycles without therapy-free intervals, the animals with transplanted leukemia died; remissions were not achieved. In all rats with autochthonous leukemia the same treatment that was additionally interrupted by therapy-free intervals of 1 week caused complete remissions. The different reactions of both leukemia types to this treatment are mainly due to their kinetic differences. The comparability of transplanted and autochthonous rat leukemias with human acute leukemia is discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00410684
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Chemotherapy of autochthonous myeloid leukemias (Chloroleukemias) in Wistar rats (1981)
    Springer
    Journal of cancer research and clinical oncology 101 (1981), S. 243-248 
    Details
    ISSN: 1432-1335
    Keywords: Autochthonous (primary) myeloid leukemia ; Chloroleukemia ; Rat ; Chemotherapy ; Autochthone (primäre) myeloische Leukämie ; Chloroleukämie ; Ratte ; Chemotherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary After injection of 15 mg/kg ethylnitrosourea (ENU) weekly for 15 weeks to adult male Wistar rats (total dose: 225 mg/kg) about 10% of the animals developed myeloid leukemias (chloroleukemias), which resemble the chronic myeloid leukemia in man (CML) (peripheral blood picture, tissue infiltration, chronic course as compared to immature-cell rat leukemias). Monotherapy with busulfan effected no remissions. The median survival time after daily treatment with busulfan was 29.5 days (range: 7–70); it was significantly shorter than that of untreated controls (median: 47.5 days, range: 22–81). After weekly application of 20 mg/kg and 50 mg/kg Cyclophosphamide the median survival time increase to 69.5 (range: 26–114) and 61.5 (range: 20–92) days, respectively. Rate and duration of remissions after repeated weekly single doses of cyclophosphamide were positively correlated with the increase in single dose; the high dose-intermittent treatment with 50 mg/kg CPA/week yielded complete remissions in all treated animals. Despite these remissions, however, no significant increase in survival time could be observed in comparison with untreated controls. The comparability of autochthonous chloroleukemias in the rat with human CML is discussed.
    Notes: Zusammenfassung Nach wöchentlicher Injektion von 15 mg/kg Äthylnitrosoharnstoffüber 15 Wochen in erwachsene männliche Wistar Ratten (Gesamtdosis: 225 mg/kg) entwickelten etwa 10% der Tiere Chloroleukämien, die eine auffallende Ähnlichkeit mit der chronischen myeloischen Leukämie (CML) des Menschen haben (peripheres Blutbild, Gewebsinfiltration, chronischer Verlauf beim Vergleich mit unreifzelligen Rattenleukämien). Eine Monotherapie mit Busulfan bewirkte keine Remissionen. Nach täglicher Behandlung mit Busulfan lag die mediane Überlebenszeit bei 29,5 Tagen (Spanne: 7–70 Tage) und war somit kürzer als die der unbehandelten Kontrolltiere (mediane Überlebenszeit: 47,5 Tage; Spanne: 22–81 Tage). Nach wöchentlicher Behandlung mit 20 mg/kg sowie mit 50 mg/kg Cyclophosphamid (CPA) stieg die mediane Überlebenszeit auf 69,5 (Spanne: 26–114) bzw. 61,5 (Spanne: 20–92) Tage an. Die Remissionsrate und die Remissionsdauer nach wöchentlich wiederholten Einzeldosen von Cyclophosphamid zeigten eine positive Korrelation zur Höhe der Einzeldosis; so bewirkte eine intermittierende Behandlung mit 50 mg/kg CPA/Woche bei allen behandelten Ratten eine komplette Remission. Trotz der Remissionen konnte jedoch kein signifikanter Anstieg der Überlebenszeit beim Vergleich mit den unbehandelten Kontrollen beobachtet werden. Die Vergleichbarkeit der autochthonen Chloroleukämie der Ratte mit der CML des Menschen wird diskutiert.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00410110
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats (1981)
    Springer
    Journal of cancer research and clinical oncology 101 (1981), S. 285-302 
    Details
    ISSN: 1432-1335
    Keywords: Yoshida sarcoma ; Descending colon ; 2-Chloroethyl-nitrosoureas ; Sprague-Dawley rats ; Yoshida-Sarkom ; Colon descendens ; 2-Chlorethyl-nitrosoharnstoffe ; Sprague-Dawley-Ratten
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die chemotherapeutische Wirkung von 12 neu entwickelten Nitrosoharnstoffen wurde vergleichend an Yoshida-Sarkom-Asziteszellen experimentell untersucht, die in die Wand des Colon descendens von Sprague-Dawley-Ratten implantiert worden waren. Cyclophosphamid sowie die Nitrosoharnstoffe BCNU, MeCCNU und Chlorozotocin dienten als positive Kontrolle. Unter den untersuchten Nitrosoharnstoffen zeigten 1-(2-Hydroxyethyl)-3-(2-chlorethyl)-3-nitrosoharnstoff (Hydroxyethyl-CNU), Chlorozotocin, 1-(2-Chlorethyl)-1-nitroso-3-(4-morpholino)-harnstoff, 1-(2-Chlorethyl)-1-nitroso-3-(1-piperidino)-harnstoff, 4-[1-(2-Chlorethyl)-1-nitroso]-3-[4-(2,6-dimethylmorpholino)]-harnstoff und 1-(2-Chlorethyl)-1-nitroso-3-(3,4-methylendioxybenzyl)-harnstoff die stärkste Aktivität in diesem Tumormodell. Auf Grund der vorliegenden Ergebnisse ist Morpholino-CNU als die erfolgversprechendste Substanz unter den neu synthetisierten BCNU-Analogen anzusehen.
    Notes: Summary The chemotherapeutic activity of 12 newly synthesized nitrosoureas was compared in tests using Yoshida sarcoma ascites cells implanted into the wall of the descending colon in Sprague-Dawley rats. Cyclophosphamide and the nitrosoureas, BCNU, MeCCNU, and chlorozotocin served as positive controls. Among the nitrosoureas tested, 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea (hydroxyethyl-CNU), chlorozotocin, 1-(2-chloroethyl)-1-nitroso-3-(4-morpholino) urea, 1-(2-chloroethyl)-1-nitroso-3-(1-piperidino) urea, 4-[1-(2-chloroethyl)-1-nitroso]-3-[4-(2,6-dimethylmorpholino)] urea, and 1-(2-chloroethyl)-1-nitroso-3-(3,4-methylenedioxybenzyl) urea were found to be the most active compounds in this tumor model. Based on the present results, morpholino-CNU is considered the most promising compound among these newly synthesized BCNU analogues.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00410114
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy (1988)
    Springer
    Journal of cancer research and clinical oncology 114 (1988), S. 183-185 
    Details
    ISSN: 1432-1335
    Keywords: Cytotoxic chemotherapy ; First line ; Second line ; Metastatic breast cancer ; Overall survival
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00417834
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Experimental chemotherapy with N′N′-bis(2-chloroethyl)-N-nitrosourea (BCNU) in autochthonous neurogenic tumors of the rat transplacentally induced by ethylnitrosourea (1982)
    Springer
    Journal of cancer research and clinical oncology 104 (1982), S. 89-98 
    Details
    ISSN: 1432-1335
    Keywords: Autochthonous primary neurogenic tumors ; Rat ; Transplacental induction ; Chemotherapy ; BCNU
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Autochthonous neurogenic tumors of the rat induced by transplacental application of ethylnitrosourea were used for the first time to study their suitability as tumor models for experimental chemotherapy. Of 189 transplacentally treated rats, 87% developed neurogenic tumors. After the initial clinical diagnosis of a neurogenic tumor, additional malignant tumors often occurred. The mean number of neurogenic tumors from 62 untreated control rats increased from 1.0 per rat at the time of randomization to 1.2 as revealed by autopsy and 1.5 tumors by histological examinations. Out of all neurogenic tumors, tumors of the brain were observed in 31%, tumors of cranial nerves in 36% (90% tumors of trigeminal nerve), tumors of spinal cord in 21%, and tumors of peripheral nerves in 10%. The median survival time until natural death of 62 control rats was 228 days. Rats with tumors of peripheral nerves lived shortest, followed by rats with tumors of cranial nerves, tumors of the spinal cord, and brain tumors. Brain tumors were mainly astrocytomas and oligodendrogliomas. The survival time of untreated rats from randomization to natural death was longest for those with brain tumors, followed by tumors of peripheral nerves, cranial nerves, and tumors of the spinal cord. There was great variation in survival time from a few days to more than 6 months. To study the responsiveness to chemotherapy, 62 rats received BCNU as a single intravenous dose of 9 and later 10 mg/kg. Sixty-two untreated control rats had a median survival time of 36 days (95% confidence interval 26–52 days), the treated rats 43.5 days (26–62 days) The difference was not statistically significant. BCNU produced a remission or a no change of neurologic symptoms in 60% (37 out of 62) in comparison to 39% (24 out of 62) in the control group (p〈0.05). The advantages and disadvantages of the present models are discussed. Due to methodical problems and the marginal response to BCNU, autochthonous neurogenic tumors of the rat are not suitable as models for chemotherapeutic studies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00402057
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...